To include your compound in the COVID-19 Resource Center, submit it here.

SillaJen and NCI to evaluate Pexa-Vec with PD-L1 and CTLA-4 antibodies

SillaJen Inc. (KOSDAQ:215600) entered into a cooperative research and development

Read the full 105 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE